Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics (PK) of BIA 9-1067 in patients
with moderate chronic hepatic impairment and in matched healthy subjects.